Development of DNA aptamer selection approach based on membrane ultrafiltration of aptamer/target complex

Background. Aptamers are small single-stranded DNA or RNA molecules that have an affinity for a specific target molecule. The main method of aptamers construction is the technology of systematic evolution of ligands with exponential enrichment (SELEX). However, the exact approach depends on the nature of target molecules, and is selected and optimized by each researcher independently. The article describes the technique of production of aptamers to the tick-borne encephalitis virus (TBEV) using membrane ultrafiltration with a molecular weight cut-off of 100 kDa. As a result, the pool of aptamers with observable affinity for TBEV is successfully selected and enriched.
The aim. To develop the technique suitable for selection of specific DNA aptamers to a live, crude TBEV suspension directly in cell culture supernatant.
Materials and methods. The selection of aptamers was carried out using a modified SELEX DNA aptamer technology in combination with semipermeable membrane ultrafiltration using Vivaspin 6 (Sartorius, Germany) concentrators of molecular weight cut-off of 100 kDa. Enrichment of a specific pool of aptamers was performed using real time polymerase chain reaction. Aptamers were sequenced with automated Sanger sequencing method. The direct virucidal effect of the aptamers was determined by the decrease in the titer of the infectious virus after incubation with the aptamer.
Results. The pool of aptamers to TBEV was selected and enriched. This aptamer pool expressed affinity both to the infectious TBEV and to the TBEV antigen. Sixteen aptamers were sequenced from this pool and four of them were synthesized and tested for antiviral activity against TBEV. No antiviral activity was observed.
Conclusions. The technique developed that can be successfully used to select aptamers to a live virus culture for the viruses comparable in size to TBEV or larger.

1. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249(4968): 505-510. doi: 10.1126/science.2200121

2. Garst AD, Edwards AL, Batey RT. Riboswitches: Structures and mechanisms. Cold Spring Harb Perspect Biol. 2011; 3(6): a003533. doi: 10.1101/cshperspect.a003533

3. Jellinek D, Green LS, Bell C, Janjić N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry. 1994; 33(34): 10450-10456. doi: 10.1021/bi00200a028

4. Kaur H, Bruno JG, Kumar A, Sharma TK. Aptamers in the therapeutics and diagnostics pipelines. Theranostics. 2018; 8(15): 4016-4032. doi: 10.7150/thno.25958

5. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med. 1998; 4(6): 655-657. doi: 10.1038/nm0698-655

6. Winkler J. Therapeutic oligonucleotides with polyethylene glycol modifications. Future Med Chem. 2015; 7(13): 1721-1731. doi: 10.4155/fmc.15.94

7. Huang Y, Zhang L, Li Z, Gopinath SCB, Chen Y, Xiao Y. Aptamer-17β-estradiol-antibody sandwich ELISA for determination of gynecological endocrine function. Biotechnol Appl Biochem. 2020; 68(4): 881-888. doi: 10.1002/bab.2008.

8. Lobigs M, Lee E, Ng ML, Pavy M, Lobigs P. A flavivirus signal peptide balances the catalytic activity of two proteases and thereby facilitates virus morphogenesis. Virology. 2010; 401(1): 80-89. doi: 10.1016/j.virol.2010.02.008

9. Wang Y, Li Z, Yu H. Aptamer-based western blot for selective protein recognition. Front Chem. 2020; 8: 570528. doi: 10.3389/fchem.2020.570528

10. Penievskaya NA. Etiotropic preparations for post-exposure tick-borne encephalitis prevention: perspective development and problems of epidemiological effectiveness evaluation. Epidemiology and Vaccinal Prevention. 2010; 1(50): 39-45. (In Russ.).

11. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology. 2003; 110(5): 979-986. doi: 10.1016/S0161-6420(03)00085-X

12. Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol. 2017; 57: 61-79. doi: 10.1146/annurev-pharmtox-010716-104558

13. Gold L, Polisky B, Uhlenbeck O, Yarus M. Diversity of oligonucleotide functions. Annu Rev Biochem. 1995; 64: 763-797. doi: 10.1146/annurev.bi.64.070195.003555

14. Thomas M, Chédin S, Carles C, Riva M, Famulok M, Sentenac A. Selective targeting and inhibition of yeast RNA polymerase II by RNA aptamers. J Biol Chem. 1997; 272(44): 27980-27986. doi: 10.1074/jbc.272.44.27980

15. Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol. 2000; 74(1): 5-13. doi: 10.1016/s1389-0352(99)00004-5

16. Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. The potential of aptamers as anticoagulants. Trends Cardiovasc Med. 2005; 15(1): 41-45. doi: 10.1016/j.tcm.2005.01.002

17. Proske D, Blank M, Buhmann R, Resch A. Aptamers-basic research, drug development, and clinical applications. Appl Microbiol Biotechnol. 2005; 69(4): 367-374. doi: 10.1007/s00253-005-0193-5

18. Zhang Z, Blank M, Schluesener HJ. Nucleic acid aptamers in human viral disease. Arch Immunol Ther Exp (Warsz). 2004; 52(5): 307-315.

19. Bolotova NA, Khasnatinov MA, Liapunov AV, Manzarova EL, Solovarov IS, Danchinova GA. Long-term trends of changes in infestation rate of the Baikal region population by ixodic ticks. Acta biomedica scientifica. 2017; 2(1): 89-93. (In Russ.). doi: 10.12737/article_5955e6b5c91407.50206187

20. Suss J. Tick-borne encephalitis in Europe and beyond – The epidemiological situation as of 2007. Euro Surveill. 2008; 13(26): 18916.

21. Dörrbecker B, Dobler G, Spiegel M, Hufert FT. Tick-borne encephalitis virus and the immune response of the mammalian host. Travel Med Infect Dis. 2010; 8(4): 213-222. doi: 10.1016/j.tmaid.2010.05.010

22. Luchinina SV, Semenov AI, Stepanova ON, Pogodina VV, Gerasimov SG, Shcherbinina MS, et al. Vaccinal prevention of tickborne encephalitis in Chelyabinsk region: Dynamics of vaccination, population immunity, analysis of TBE cases in vaccinated persons. Epidemiology and Vaccinal Prevention. 2016; 1(86): 67-76. (In Russ.).

23. Pogodina VV, Levina LS, Skrynnik SM, Travina NS, Karan LS, Kolyasnikova NM et al. Tick-borne encephalitis with fulminant course and lethal outcome in patients after plural vaccination. Problems of Virology. 2013; 58(2): 33-37. (In Russ.).

24. Subbotin AV, Semenov VA, Smirnov VD, Shcherbinina MS, Pogodina VV. A case of chronic tick-borne encephalitis in vaccinated person. Epidemiology and Vaccinal Prevention. 2014; 3: 76. (In Russ.).

25. Solovarov IS, Khasnatinov MA, Danchinova GA, Liapunov AV, Bolotova NA, Manzarova EL, et al. Assessment of neutralizing properties of DNA-aptamers and extracts of medicinal herbs against the tick-borne encephalitis virus. Acta biomedica scientifica. 2017; 2(1): 84-88. (In Russ.). doi: 10.12737/article_5955e6b5aad2e3.30269730

26. Khasnatinov MA, Danchinova GA, Zlobin VI, Liapunov AV, Arbatskaya EV, Tchaporgina EA. Tick-borne encephalitis virus in Mongolia. Siberian Medical Journal (Irkutsk). 2012; 111(4): 9-12. (In Russ.).

27. Gould EA, Clegg JCS. Growth, titration and purification of togaviruses. In: Mahy BWJ (ed.). Virology: A practical approach. Oxford; 1985: 43-48.